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Background: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive
soft tissue sarcomas with dismal prognosis. Pathological and genetic markers
may predict more aggressive behavior in MPNSTs but have uncommonly been
investigated, and few are used in daily practice. This study reviews the prognostic value
of immunohistochemical markers and genetic alterations in MPNST.
Methods: A systematic search was performed in PubMed and Embase databases
according to the PRISMA guidelines. Search terms related to ‘MPNST’ and ‘prognostic’
were used. Studies investigating the association of immunohistochemical markers or
genetic alterations with prognosis were included. Qualitative synthesis was performed on
all studies. A distinction was made between univariable and multivariable associations.
Results: Forty-six studies were included after full-text screening. Sixty-seven different
immunohistochemical markers were investigated. Absence of S100 and H3K27me3 and
high Ki67 and p53 staining was most commonly independently associated with worse
survival and disease-free survival. Several genetic alterations were investigated as well
with varying association to survival. TP53, CDK4, RASSF1A alterations were
independently associated with worse survival, as well as changes in chromosomal
length in Xp, 10q, and 16p.
Conclusions:MPNSTs harbor complex and heterogeneous biology. Immunohistochemical
markers and genetic alterations have variable prognostic value. Absence of S100 and
H3K27me3 and increased Ki67 can be of prognostic value. Alterations in TP53 or increase in
p53 stainingmay distinguishMPNSTswith worse outcomes. Genetic alterations and staining
of other cell cycle regulatory and Ras pathway proteins may also help stratifying patients with
worse outcomes. A combination of markers can increase the prognostic value.
Keywords: malignant peripheral nerve sheath tumors, prognosis, molecular, clinicopathologic, markers, genesDecember 2020 | Volume 10 | Article 5940691
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Malignant peripheral nerve sheath tumors (MPNSTs) are rare
and aggressive soft tissue sarcomas (STS) that carry a dismal
prognosis (1–3). Neurofibromatosis type 1 (NF1) patients have
an increased risk of developing these tumors and encompass
approximately 25–50% of MPNST patients (1–5). The NF1 gene
is commonly affected in MPNSTs which causes loss of the
neurofibromin protein which inhibits the Ras enzyme (6).
Activation of the Ras pathway leads to upregulation of the
mitogen-activated protein (MAPK) and phosphoinositide 3-
kinase (PI3K) pathways (7). Besides the common knockdown
of NF1, alterations in several genes including TP53, SUZ12, EED,
PTEN, and CDKN2A as well as upregulation of several tyrosine
kinases contribute to the formation of MPNST (8–12). MPNSTs
are known for harboring complex genomic alterations, but
despite our increasing understanding of underlying biology,
prognosis has not ameliorated the past decades and median
survival stagnates at 5–6 years (2, 3).
Staging of MPNSTs is important to increase accuracy of
outcome prediction, but it may also facilitate treatment
stratification. However, the clinical American Joint Committee
of Cancer (AJCC) STS staging system is less applicable in
MPNST (4, 5, 13). The histologic Fédération Nationale des
Centres de Lutte Contre le Cancer (FNCLCC) grading system
used in STS is of prognostic value since low grade MPNST
(FNCLCC grade 1) has improved survival (2). However, only
10% of MPNSTs are grade 1, and the FNCLCC grading can likely
only distinguish prognosis between grades 1 and 3 (2, 5).
Moreover, the histological distinction between low-grade
MPNST and benign neurofibroma with atypia is difficult as
objective criteria are lacking, causing interobserver variability.
In the context of NF1, the diagnosis of progression to MPNST is
even more challenging. Recently, a consensus view has been
published defining “atypical neurofibromatous neoplasm of
uncertain biologic potential (ANNUBP)” as an intermediate
lesion in NF1 patients (14). While driver mutations are
increasingly being studied, the transition of neurofibromas to
MPNSTs is not yet fully understood. Clinical parameters as
predictors of outcome have been studied more commonly, but
independent predictors are found inconsistently (3). Although
radiation-induced MPNSTs have repeatedly been associated with
worse survival, the influence of NF1 disease on survival has been
subject of debate (3, 13, 15). Better classification systems for
MPNSTs are therefore urgently needed.
Currently, surgery remains the only proven treatment to
improve survival (1–3). Chemotherapy has limited effect in
localized disease, and its use is controversial. Some studies suggest
a minor benefit in high-grade, large, and deep MPNST (16–18).
Moreover, 10–20% of patients present with metastatic or
unresectable disease and up to 50% of patients will develop
metastases over time (1–5, 13, 19). Targeted therapies are
warranted, but so far none have been proven effective (20).
Immunohistochemical and genetic markers may predict more
aggressive behavior in MPNSTs, but their association with
oncological outcome has uncommonly been investigated and few
are yet used in daily practice for prognostication. For this reason thisFrontiers in Oncology | www.frontiersin.org 2systematic review set out to summarize current knowledge on the
prognostic value of immunohistochemical and genetic markers.
Such markers may enhance prognostication and aid in elucidating
driver mutations of malignancy.METHODS
Literature Search
A systematic search was performed in Embase and PubMed
databases according to the Preferred Reporting Items for
Systematic Reviews and Meta-analysis (PRISMA) guidelines, in
order to identify all potentially relevant articles as of March 2020.
The string was built with the help of a professional librarian
using search terms related to ‘MPNST’ and ‘prognostic’. The
exact search syntaxes for PubMed and Embase are shown in
Supplementary Table 1. Studies were included that evaluated
the association of immunohistochemical markers and genetic
alterations to oncological outcomes in MPNST patients.
Exclusion criteria included lack of full text or studies without
specific analyses fitting our inclusion criteria. The initial review
was conducted by two independent authors (EM. and IA).
Disagreements were solved through discussion in which one
additional author was involved (CV).
Data Extraction and Synthesis
Data extracted from studies included: study period, total number
of patients, mean age and range, percentage NF1 patients,
markers and genetic alterations investigated for prognostic
value, and analyses used to identify prognosticators. For
all markers and genetic alterations investigated additional
information was extracted: number of patients with survival
data, population with ‘positive’ test, oncological outcome
analyzed, and whether its prognostic value was corrected for
common clinical prognostic factors. Whenever the marker was
independently associated with outcome, the hazard ratio was
noted. Common factors for which could have been adjusted in
multivariable models included: age, presence of NF1, tumor size,
tumor site, metastasis at diagnosis, tumor depth, tumor grade,
and surgical margin (3). All results of the predictive value of
markers were presented or re-calculated to represent the marker
cut-off as a negative predictor of survival. Qualitative synthesis
was performed for all studies, summarizing results based on type
of analysis. Immunohistochemical markers were further stratified
into markers of differentiation, receptors and their ligands, Ras
pathway, cell cycle regulation, p53 pathway, vascularization, and
others. For each immunohistochemical marker cumulative
incidence of univariable and multivariable association to
survival (disease-specific or overall) or disease-free survival
(recurrence, metastasis, or both) were calculated.RESULTS
After removal of duplicates, a total of 1,882 articles were identified
in PubMed and Embase databases (Figure 1). Title and abstractDecember 2020 | Volume 10 | Article 594069
Martin et al. Prognostic Markers in MPNSTscreening resulted in 55 potentially relevant articles, of which 46
were selected for qualitative synthesis after full-text screening.
Mean age differed between 11 and 50 years old (range of all
patients 1–94). Prevalence of NF1 patients in study populations
ranged from 0 to 100% (mean: 48.0%). Immunohistochemical
markers were studied exclusively in 36 studies, genetic alterations
in seven studies, and both in three studies (Table 1). A total of 67
different immunohistochemical markers and numerous genetic
alterations were evaluated (Table 2, Figure 2).Differentiation
Seven mesenchymal and neuronal differentiation markers were
evaluated (Table 2), most commonly S100 (4, 45, 46, 56, 58, 62).
In univariable analysis complete absence of S100 was found
negatively associated with survival in four/six studies. Two
studies showed the absence of S100 to be an independent
predictor of worse survival with HR 4.5 (95% CI: 2.0–12.1)
and HR 6.6 (95% CI: 1.8–23.8) (4, 62). All seven markers were
also evaluated for association with disease-free survival (DFS).
Negative S100 staining was associated with worse DFS in two/
four studies, of which one study showed an independent
association (HR 4.2, 95% CI: 1.5–12.3) (62). Negative smooth
muscle actin (SMA) and CD57 staining were also found
associated with worse DFS in univariable analysis in one study,
but not in multivariable analysis (58).Frontiers in Oncology | www.frontiersin.org 3Vascularization
Microvascular density (MVD) and vascular epithelial growth
factor (VEGF) staining were evaluated as vascularization
markers (Table 2) (4, 28, 30, 57, 59). High MVD was
associated with worse survival in one/four studies. This
association was also significant in multivariable analyses (HR
7.3, 95% CI: 1.4–38.5) (57). High VEGF staining was associated
with worse survival in one/two studies, but this was not studied
in a multivariable model (59). No markers were studied for
association with DFS.
Receptors and Ligands
Immunohistochemical expression of nine different receptors or
their ligands were evaluated, most commonly the epidermal
growth factor receptor (EGFR, Table 2) (4, 29, 37–39, 55, 56,
63, 64). Increased EGFR staining was associated with worse
survival in univariable analysis in two/three studies, but this was
not evaluated in a multivariable model (4, 39, 54). Increased
phosphorylated MET (p-MET), C-X-C motif chemokine
receptor 4 (CXCR4), and low fibroblast growth factor receptor
1 (FGFR1) staining were also associated with worse survival in
univariable analysis, but only p-MET (HR 1.04, 95% CI: 1.0–1.1)
and FGFR1 (HR 2.8, 95% CI: 1.2–6.7) were independently
associated with survival (37, 56, 63, 64). Increased EGFR and
FGFR4 were associated with worse DFS, but only in univariable
analyses (39, 64). On a genetic level, no amplification of FGFR1FIGURE 1 | Flowchart depicting study selection.December 2020 | Volume 10 | Article 594069





NF1 Markers and genetic alterations Analysis typea





Benassi et al. (22) NA 17 NA NA Laminin receptor IHC
Benassi et al. (23) NA 15 NA NA MMP-2, MMP-9, TIMP-2 IHC




43.8% p53, p-RB, CDK2, CDK4, cyclin D1, cyclin D3, cyclin E1, p14, p16, p18, p21, p27,
MDM2, Ki67
IHC




58.3% Xq loss, 10q loss, 16p gain, 16q loss, 5p gain, 2q gain, 6q gain, 7q gain, Xp loss,
10p loss, 4q loss, 20q gain, 1q gain
aCGH
Cleven et al. (26) 1979–
2007
162 NA 49.4% H3K27me3 IHC






Endo et al. (28) 1964–
2008
99 NA 33.3% p14, p15, p16, Ki67 IHC
Endo et al. (7) 1964–
2010
88 NA 40.9% p-Akt, p-mTOR, p-S6RP, p-p70S6K, p-4E-BP1, p-MEK, p-ERK, Ki67 IHC
Fan et al. (29) NA 56 NA NA MET, MDM2, p53 IHC
Fukushima et al. (30) 1964–
2011
82 NA 39.0% HIF-1a, HIF-2a, MVD, Ki67 IHC










Halling et al. (33) NA 28 39 (15–
84)
50.0% p53 IHC




50.0% TP53, MDM2 aCGH, RT-PCR
Holtkamp et al. (35) NA 36 40 (13–
78)
61.1% MMP-13, p53 codon PCR, IHC
Holtkamp et al. (36) NA 34 NA 76.5% CDKN2A MLPA




53.3% HA, HAS1, HAS2, HAS3 IHC





Keizman et al. (39) 1994–
2006
51 41 (NA) 51.0% EGFR IHC




41.2% CHFR, Ki67 IHC




44.4% Survivin, TK1, TOP2A IHC
Kourea et al. (42) NA 35 NA (NA) NA p53, p-RB, p21, p27, cyclin D1, cyclin E, Ki67 IHC
Krawczyk et al. (43) 1992–
2013
26 10 (NA) 34.6% Survivin, cyclin D1, osteopontin, fibronectin, p53 IHC
Kresse et al. (44) NA 7 47 (24–
78)
NA 17q23.2-q25.3, TOP2A, ETV4, HOXB7, BIRC5, miR142p-3p, miR142-5p, miR201,
miR21, miR338
aCGH, RT-PCR









54.8% S100, MDM2, desmin IHC

















NA 20 (15–70) 100% MAGEA3 Methylation-
specific PCR





Panse et al. (52) NA 39 NA NA p-STAT3 IHC
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Torres et al. (56) 1986–
2006
96 NA 57.3% MET, HGF, p-MET, p53, S100 IHC






58.6% MCD, MVD, Ki67 IHC
Wang et al. (58) 2001–
2012
43 49 (NA) 14.0% S100, vimentin, GFAP, NSE, Ki67, SMA, CD57 IHC




50.0% VEGF, MVD IHC
Watanabe et al. (60) NA 49 41 (17–
86)
44.9% p53, Ki67, MDM2, p21 IHC
Yu et al. (61) NA 123 NA 38.2% SOX5, NOL1, MLF2, FOXM1, FKBP4, CDK4, TSPAN31, ERBB2, MYC, TP53,
SOX5, FOXM1, Myc, p53
aCGH, RT-PCR,
FISH, IHC




44.0% S100, Ki67, vimentin, NF, GFAP IHC




0.0% CXCR4, CXCL12, cyclin D1 IHC
Zhou et al. (64) NA 63 NA NA FGFR1, FGFR2, FGFR4, FGFR1 FISH, IHC




51.4% S100, Ki67, p53, VEGF, EGFR, p-MEK IHCFrontiers in Oncology | www.frontiersin.org December 2020 | Volume5aUsed for correlation with outcome.
4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1; aCGH, array-based comparative genomic hybridization; CDK, cyclin dependant kinase; CHFR, checkpoint with
forkhead-associated domain and ring finger; COX-2, cyclooxygenase-2; CXCR4, C-X-C motif chemokine receptor 4; CXCL12, C-X-C motif chemokine ligand 12; EGFR, epidermal growth
factor receptor; ERK, extracellular signal-regulated kinases; FISH, fluorescence in situ hybridization; FGFR, fibroblast growth factor receptor; FOXM1, forkhead box protein M1; GFAP, glial
fibrillary acidic protein; H3K27me3, trimethylation of lysine 27 of histone H3; HA, hyaluronan; HAS, hyaluronan synthase; HIF, hypoxia-inducible factor; IHC, immunohistochemistry; MCD,
mast cell density; MDM2, mouse double minute 2 homolog; MEK, mitogen-activated protein kinase kinase; Met, metastasis; MLPA, multiplex ligation-dependent probe amplification;
MMP-13, matrix metallopeptidase 13; mTOR, mammalian target of rapamycin, MVD, microvessel density; N, total number of patients; NA, not available; NF1, neurofibromatosis type 1p-,
phosphorylated; RASSF1A, Ras association domain family member 1, isoform A; RT-PCR, reverse transcription polymerase chain reaction; S6RP, ribosomal protein S6; SMA, smooth
muscle actin; STAT3, Signal transducer and activator of transcription 3; TIMP-2, tissue inhibitor of metalloproteinase 2; TK1, thymidine kinase 1; TOP2A, topoisomerase 2-alpha; VEGF,
vascular endothelial growth factor.TABLE 2 | Prognostic value of immunohistochemical markers.
Marker N Survivala N Disease-free survivala
Univariate Multivariate Univariate Multivariate
+ NsA + − + NA + −
Differentiation
S100 7 57% 25% 50% 25% 4 50% 50% 50% 0%
GFAP 2 0% NA NA NA 2 0% NA NA NA
Vimentin 2 0% NA NA NA 2 0% NA NA NA
NSE 1 0% NA NA NA 1 0% NA NA NA
SMA 1 0% NA NA NA 1 100% 0% 0% 100%
Desmin 1 0% NA NA NA 1 0% NA NA NA
CD57 1 0% NA NA NA 1 100% 0% 0% 100%
Vascularization
MVD 4 25% 0% 100% 0% 0 NA NA NA NA
VEGF 2 50% 100% 0% 0% 0 NA NA NA NA
Receptors and ligands
EGFR 3 67% 100% 0% 0% 1 100% 100% 0% 0%
MET 2 0% NA NA NA 1 0% NA NA NA
p-MET 1 100% 0% 100% 0% 0 NA NA NA NA
HGF 1 0% NA NA NA 0 NA NA NA NA
CXCR4 1 100% 0% 0% 100% 1 0% NA NA NA
CXCL12 1 0% NA NA NA 1 0% NA NA NA
FGFR1 1 100% 0% 100% 0% 1 0% NA NA NA
FGFR2 1 0% NA NA NA 1 0% NA NA NA
(Continued)10 | Article 594069
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Marker N Survivala N Disease-free survivala
Univariate Multivariate Univariate Multivariate
+ NsA + − + NA + −
FGFR4 1 0% NA NA NA 1 100% 0% 0% 100%
HA 1 100% 0% 0% 100% 1 100% 0% 100% 0%
HAS1 1 0% NA NA NA 1 0% NA NA NA
HAS2 1 0% NA NA NA 1 0% NA NA NA
HAS3 1 0% NA NA NA 1 0% NA NA NA
Decorin 1 100% 100% 0% 0% 0 NA NA NA NA
Ras pathway
p-MEK 2 0% NA NA NA 0 NA NA NA NA
NF 1 0% NA NA NA 1 0% NA NA NA
p-ERK 1 0% NA NA NA 0 NA NA NA NA
p-Akt 1 0% NA NA NA 0 NA NA NA NA
p-mTOR 1 100% 0% 100% 0% 0 NA NA NA NA
p-p70S6K 1 0% NA NA NA 0 NA NA NA NA
p-4E-BP1 1 0% NA NA NA 0 NA NA NA NA
p-S6RP 1 100% 0% 100% 0% 0 NA NA NA NA
COX-2 1 100% 0% 100% 0% 0 NA NA NA NA
Myc 1 100% 0% 0% 100% 0 NA NA NA NA
Cell cycle regulation
p53 10 40% 25% 75% 0% 3 67% 50% 50% 0%
MDM2 4 0% NA NA NA 2 50% 100% 0% 0%
Cyclin D1 4 25% 0% 100% 0% 3 33% 0% 100% 0%
p21 3 0% NA NA NA 1 0% NA NA NA
Cyclin E 2 0% NA NA NA 1 0% NA NA NA
p-RB 2 0% NA NA NA 1 100% 100% 0% 0%
p14 2 100% 0% 50% 50% 0 NA NA NA NA
p16 2 50% 0% 100% 0% 0 NA NA NA NA
p27 2 50% 100% 0% 0% 1 0% NA NA NA
p15 1 0% NA NA NA 0 NA NA NA NA
p18 1 0% NA NA NA 0 NA NA NA NA
FOXM1 1 100% 0% 100% 0% 0 NA NA NA NA
SOX5 1 0% NA NA NA 0 NA NA NA NA
CDK2 1 0% NA NA NA 0 NA NA NA NA
CDK4 1 0% NA NA NA 0 NA NA NA NA
Cyclin D3 1 0% NA NA NA 0 NA NA NA NA
HIF1a 1 100% 0% 100% 0% 0 NA NA NA NA
HIF2a 1 0% NA NA NA 0 NA NA NA NA
CHFR 1 100% 0% 100% 0% 0 NA NA NA NA
Epigenetic modulation
H3K27me3 3 67% 0% 50% 50% 1 0% NA NA NA
TOP2A 2 100% 50% 0% 50% 1 100% 100% 0% 0%
Other
Ki67 13 62% 0% 25% 75% 5 40% 0% 50% 50%
Survivin 2 50% 0% 0% 100% 1 0% NA NA NA
ATRX 1 100% 0% 100% 0% 0 NA NA NA NA
TK1 1 100% 0% 0% 100% 0 NA NA NA NA
MCD 1 0% NA NA NA 0 NA NA NA NA
p-STAT3 1 100% 100% 0% 0% 1 0% NA NA NA
Osteopontin 1 0% NA NA NA 1 0% NA NA NA
Fibronectin 1 0% NA NA NA 1 0% NA NA NA
MMP-2 0 NA NA NA NA 1 0% NA NA NA
MMP-9 0 NA NA NA NA 1 0% NA NA NA
MMP-13 0 NA NA NA NA 1 0% NA NA NA
TIMP-2 0 NA NA NA NA 1 0% NA NA NA
Laminin receptor 0 NA NA NA NA 1 100% 100% NA NAFrontiers in Oncology | www.frontiersin.org 6 December 2020 | Volume 10 | Article 5aUnivariate analysis: significant effect (+), not significant effect (−); Multivariate analysis: not performed (NA), significant effect (+), nog significant effect (−).
4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1; CDK, cyclin dependent kinase; CHFR, checkpoint with forkhead-associated domain and ring finger; COX-2, cyclooxygenase-2;
CXCR4, C-X-C motif chemokine receptor 4; CXCL12, C-X-C motif chemokine ligand 12; DFS, disease-free survival (either time to recurrence, metastasis, or both); EGFR, epidermal growth factor
receptor; ERK, extracellular signal-regulated kianses; FGFR, fibroblast growth factor receptor; FOXM1, forkhead box protein M1; GFAP, glial fibrillary acidic protein, H3K27me3, trimethylation of lysine
27 of histone H3; HA, hyaluronan; HAS, hyaluronan synthase; HIF, hypoxia-inducible factor; MCD,mast cell density; MDM2, mouse double minute 2 homolog, MEK, mitogen-activated protein kinase
kinase;MMP,matrixmetalloproteinase;mTOR,mammalian target of rapamycin;MVD,microvessel density; N, number of studies, NA, not applicable; NF, neurofibromin; p-, phosphorylated, S, survival
(either disease-specific or overall); S6RP, ribosomal protein S6; SMA, smooth muscle actin; STAT3, Signal transducer and activator of transcription 3; TIMP-2, tissue inhibitor of metalloproteinase 2;
TK1, thymidine kinase 1, TOP2A, topoisomerase 2-alpha; VEGF, vascular endothelial growth factor.94069
Martin et al. Prognostic Markers in MPNSTon fluorescence in situ hybridization (FISH) was associated with
worse survival and DFS in univariable analysis (Supplementary
Table 2) (64). Copy number alterations in ERBB2 were not
associated with survival (61).
Extracellular Matrix
Twelve extracellular matrix markers were studied, of which none
was evaluated more than once (Table 2) (22, 23, 35, 37, 38, 43).
Only increased hyaluronan (HA) and decorin staining were
associated with decreased survival, but none in a multivariable
model (36, 37). Increased HA and laminin receptor were associated
with worse DFS, but only HA was associated with worse DFS in a
multivariable model (HR 5.7, 95% CI: 1.2–26.4) (22, 37).
Ras Pathway
Ten different Ras pathway proteins were stained, but only
phosphorylated MAPK kinase (MEK) was evaluated more than
once (Table 2) (4, 7, 32, 61, 62). Increased phosphorylated
mammalian target of rapamycin (p-mTOR), phosphorylated
ribosomal protein S6 (p-S6RP), cyclooxygenase-2 (COX-2),
and Myc staining were associated with worse survival
univariable analysis (7, 32, 61). Only increased p-mTOR (HR
2.6, 95% CI: 1.3–5.5), p-S6RP (HR 2.5, 95% CI: 1.3–5.5), and
COX-2 (HR 3.0, 95% CI: 1.1–10.2) staining were independently
associated with worse survival (7, 32). No Ras pathway associated
immunohistochemical marker was found associated with DFS.
On a genetic level, copy number alterations of MYC were not
associated with survival (61). Methylation of RASSF1A gene wasFrontiers in Oncology | www.frontiersin.org 7associated independently with worse survival in one study (HR
5.2, 95% CI: 1.4–19.4, Supplementary Table 2) (27). This
association was however only found in the NF1 subpopulation.
Cell Cycle Regulation
Sixteen immunohistochemical markers of cell cycle regulation
were evaluated, most commonly p53 (Table 2) (4, 24, 26, 28, 29,
33, 40, 42, 43, 46, 47, 51, 53, 56, 60, 61, 63). Low p14, p16,
checkpoint with forkhead-associated domain and ring finger
(CHFR), and increase in p53, p14, cyclin D1, p27, and
forkhead box protein M1 (FOXM1) staining were associated
with worse survival in univariable analysis (4, 26, 28, 40, 42, 43,
51, 56, 61). Positive p53 staining was independently associated
with survival in three/four studies (HR 1.8, 95% CI: 1.0–3.3, HR
2.3, 95% CI: 1.2–4.5, and HR 6.4, 95% CI: 1.5–29.0) (4, 24, 56).
Increased staining of cyclin D1 (HR 15.9, 95% CI: 2.0–125.0),
HIF1a (HR 8.3, 95% CI: 2.8–28.9), FOXM1 (HR 1.9, 95% CI:
1.1–3.3), and decreased staining of p16 (HR 2.2, 95% CI: 1.5–3.2)
and p14 (HR 2.7, 95% CI: 1.8–4.2) were also independently
associated with worse survival in one study each (28, 30, 43, 61).
Positive staining of p53, MDM2, cyclin D1, and p-RB were
associated with worse DFS in univariable analysis (29, 42, 43).
Only cyclin D1 (HR 11.1, 95% CI: 2.8–47.6) and p53 (HR 3.2,
95% CI: 1.0–10.4) were independently associated with worse DFS
in one study (43). On a genetic level, mutation, homozygous loss,
or loss of heterogeneity of TP53 was associated with worse
survival in two/three studies (Supplementary Table 2) (34, 35,
61). The copy number gain of MDM2 and CDK4 as well asFIGURE 2 | Cellular pathways in MPNST.December 2020 | Volume 10 | Article 594069
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survival (34, 61). Gain (HR 4.2, 95% CI: 1.4–12.4) or
amplification (HR 2.0, 95% CI: 1.0–4.0) of CDK4 was
independently associated with worse survival (59). The
combination of either MDM2 gain or TP53 aberration made a
high risk group (16%) for worse survival with a HR 3.4 (95% CI:
1.4–8.3) (34). In the same study, a gene expression profile was
made and a score of ≥0.12 was present in 66.7% of the population
which was associated with worse survival as well (HR 4.0, 95%
CI: 1.3–12.1). Another study on DNA copy number changes
found a significant association with worse survival for gain at
17q23.2–25.3, but not in several related genes or micro-RNAs in
this region (44). The association was not evaluated in a
multivariable model. A gain in FOXM1 was worse survival in
another study (61). Only the polymorphism of p53Pro72 was
associated with worse DFS in one study (35). This association
was not evaluated in a multivariable model.
Epigenetic Modulation
Two epigenetic modulating proteins were investigated as
immunohistochemical markers (Table 2) (26, 41, 51, 53, 54).
Loss of trimethylation of lysine 27 of histone H3 (H3K27me3)
and increased topoisomerase 2-alpha (TOP2A) staining were
both associated with decreased survival (26, 41, 51, 54). Only
H3K27me3 was independently associated with worse survival
(HR 2.6, 95% CI: 1.2–5.7) in one out of two studies (26, 51).
Increased TOP2A staining was also associated with worse DFS in
one study (54). High copy number changes of TOP2A was not
associated with worse survival (Supplementary Table 2) (44).
Other
Thirteen other immunohistochemical markers were studied,
most commonly the proliferation marker Ki67 (4, 7, 24, 30, 31,
40–43, 48, 52, 54, 57, 58, 60–62). On average a cut-off at 20.9%
(range: 5–30%) for high Ki67 staining was used and it was
significantly associated with worse survival in 8/12 studies, of
which two studies showed an independent association (HR 2.4,
95% CI: 1.1–4.9 and HR 10.2, 95% CI: 3.6–32.1) (28, 30).
Increased survivin, thymidine kinase 1 (TK1), phosphorylated
signal transducer and activator of transcription 3 (p-STAT3),
and hypoxia-induced factor 1-alpha (HIF1a) and decreased
ATRX staining were associated with worse survival (30, 41,
48). Both decreased ATRX (HR 5.3, 95% CI: 1.4–20.4) and
positive HIF1a staining (HR 8.3, 95% CI: 2.8–28.9) were
independently associated with worse survival (30, 48). One
study showed that when there was high survivin and high TK1
staining or low survivin and high TOP2A staining a high risk
group of patients could be stratified with HR 4.6 (95% CI: 1.5–
14.4) (41). Increased staining of Ki67 and laminin receptor were
associated with worse DFS (22, 31, 62). Only high Ki67 staining
was shown to have an independent association with worse DFS
in one/two studies (HR 3.8, 95% CI: 1.7–8.5) (62). Four studies
investigated several other genetic alterations, including two on
BIRC5, the gene encoding surviving (21, 25, 44, 50). One out of
two studies showed that an increase in BIRC5 mRNA was
associated with worse survival in univariable analysis (21).
Gain at 17q23.2–25.3 was associated with worse survival inFrontiers in Oncology | www.frontiersin.org 8univariable analysis in another study (44). One study
investigated the effect of chromosomal gains and losses and
showed an independent effect on worse survival for Xq loss (HR
3.6, 95% CI: 1.6–8.3), 10q loss (HR 3.2, 95% CI: 1.4–7.7), and 16p
gain (HR 2.5, 95% CI: 1.0–6.2) (25). Together a high risk group
(63% of population) was obtained for either gain or loss which
resulted in a HR 11.0 (95% CI: 3.5–35.0) after correction for
several clinical characteristics. A gain in SOX5 and NOL1 were
associated with worse survival in one study, but only in
univariable analyses (61). Finally, methylation of MAGEA3 was
also associated with worse survival in univariable analysis (50).DISCUSSION
he underlying biology of MPNSTs remains complex as is
highlighted by the diverse findings of studies included in this
review. Many markers and genetic alterations have been proposed
to be of prognostic value, yet outcomes are infrequently repeated.
Alterations in TP53 or its resulting increased p53 staining were
commonly found associated with survival and DFS as were several
other proteins and genes involved in cell cycle regulation. Epigenetic
modulatory proteins, especially loss of H3K27me3, and more
general markers as absence of S100 and increased Ki67 were
commonly found to be of prognostic value too.
Prognostication in MPNST
The predictive value of clinical parameters including patient and
tumor characteristics has been studied more commonly than
immunohistochemical or genetic biomarkers in MPNST.
Increasing age, large tumor size, metastatic disease at diagnosis,
and tumors not amenable to complete resection are the most
commonly found predictors of worse survival in MPNST (2, 3, 5,
13, 45, 65). This emphasizes the importance of early diagnosis of
MPNST in order to completely resect tumors, along with finding
new systemic therapies to improve the prognosis of irresectable and
metastatic disease. Non-extremity tumor sites have also been shown
to have a negative impact on survival; however, this may be more
true for those arising in retroperitoneal or pelvic sites (1, 3, 5, 13, 66).
Tumor depth used to be incorporated for prognostication in the
AJCC staging system for STS, but has varyingly been shown to be of
prognostic value in MPNST (2, 3, 5, 13, 45, 65). The importance of
NF1 disease has also been subject of debate. Ameta-analysis in 2012
showed no difference in survival for patients in papers published
after 2000 (15). However, recent large cohorts did find an
independent association with worse survival for NF1 patients (3,
13, 67, 68). Altogether, clinical parameters seem to be able to predict
some part of a patient’s course of disease. The addition of tumor
biology to clinical parameters may further increase our ability to
stratify subgroups of patients based on prognosis. TP53 is one of the
few recurrently mutated genes found in MPNST. TP53 mutations
and high p53 staining were independently associated with survival
or DFS in five different studies (4, 24, 34, 43, 56). This may indicate
that aberrations in this gene may indeed be of clinical importance.
Other genes involved in cell cycle regulation such as CDKN2A and
downstream proteins are commonly altered and may not only
contribute to tumorigenesis but also be of clinical significance,December 2020 | Volume 10 | Article 594069
Martin et al. Prognostic Markers in MPNSTsupporting a belief that dysregulations in this cellular pathway are of
overall importance. Loss of polycomb regressive complex 2 (PRC2)
complex has recently been shown to be common inMPNSTs due to
mutations in EED and SUZ12 (9, 69). This results in loss of
H3K27me3 which can reliably distinguish high-grade MPNSTs
from their benign counterparts by immunohistochemistry (26,
70). MPNSTs without loss of H3K27me3 staining may also be
associated with less aggressive behavior as many low-grade
MPNSTs are known to retain this expression (14, 26). Preclinical
research on targeted therapies has most frequently shown
promising results targeting proteins in the Ras pathway, especially
when combined with other target drugs, but unfortunately no
clinical trial has proven benefit to date (20). Activated proteins in
the Ras pathway, including p-mTOR, p-4E-BP1, p-S6RP, COX-2,
and Myc as well as methylation of RASSF1A may however predict
worse survival (6, 7, 27, 32). Targeting vascular pathways in
MPNSTs may be beneficial, but unfortunately few studies have
focused on this. Studies included in this review also showed that
increased vascularity, as evidenced by increased microvascular
density as well as increased expression of VEGF, may be
associated with more aggressive biological behavior (57, 59). It
seems that many other targets may be of prognostic value as well
emphasizing the need for further research into MPNST tumor
biology. Survivin markers may for instance stratify a subgroup of
patients and survivin has been shown a viable target in a xenograft
mouse model (71). Seeing as MPNSTs are heterogenic and markers
such as p53 are not beMPNST specific, combined scores of different
markers and genetic alterations may be of most clinical importance.
Four studies in this review highlight this phenomenon
demonstrating increased prognostic value when markers are
combined (25, 28, 34, 41).
Strengths and Limitations
Unfortunately, due to the large heterogeneity of published
studies meta-analyses were not presumed feasible. All studies
included in this review were retrospective of nature inherently
harboring bias. None of the markers and genetic alterations
found in these studies were prospectively validated. Moreover,
many did not evaluate the prognostic value of their markers in a
multivariable model nor on their discriminative ability. Studies
that evaluated the prognostic value of markers in a multivariable
model were nonetheless not always capable to correct for all
common clinical variables. MPNSTs are rare sarcomas, which in
combination with their complex biology, make it difficult to
obtain enough cases to create valuable models. But as shown in
this review, several markers and genetic alterations may already
be of clinical importance as they have shown an independent
association with survival in addition to clinical parameters.
Future research should therefore be encouraged to replicate
these results using larger datasets obtained by large-scale
international collaborations. Important immunohistochemicalFrontiers in Oncology | www.frontiersin.org 9staining may include Ki67, S100, p53, and H3K27me3 in all
patients, and possibly further staining of proteins associated with
cell cycle regulation. In turn individual prediction models for
MPNST patients specifically may arise taking their significant
heterogeneity into account. Such models may better elucidate
patient selection for (neo)adjuvant treatment and targeted
therapies, which should then be validated in a prospective
database. But as MPNSTs remain rare entities one may also
turn to exploratory analyses using machine learning techniques
on large STS genetic databases to identify attractive genes as
biomarkers or prognostic markers in subtypes of STS (72).CONCLUSION
MPNSTs harbor complex and heterogenic biology and currently
lack adequate staging systems. Immunohistochemical markers and
genetic alterations are varyingly of prognostic value. Absence of
S100 and H3K27me3 and increased Ki67 staining were commonly
found to be of independent prognostic value alongside of clinical
parameters. Alterations in TP53 or its consequential increase in p53
staining seems to distinguish a subgroup of MPNSTs with worse
outcomes. Immunohistochemical staining and associated genetic
alterations of proteins involved in cell cycle regulation and the Ras
pathway may also help stratifying patients with worse outcomes.
Other markers will likely need further evaluation for validation. A
combination of markers may increase the prognostic value.DATA AVAILABILITY STATEMENT
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